Federal employee program sets new Zepbound coverage rules effective July 1

The Blue Cross Blue Shield Federal Employee Program will require members to try at least two oral weight-management medications before it covers Zepbound, under a policy approved June 11, 2026 and effective July 1, 2026 ^[1]. The FEP Pharmacy and Medical Policy Committee approved policy 5.99.031, which sets the prior-approval rules for the tirzepatide drug ^[1].

What members would have to document

All of the policy's conditions must be met. Patients must be 18 or older and have a body mass index of 30 or higher, or a BMI of 27 or higher with established cardiovascular disease or at least one weight-related condition such as type 2 diabetes, dyslipidemia or hypertension ^[1].

Patients must also show inadequate response, intolerance or contraindication to at least two oral weight-management medications. The policy names benzphetamine, diethylpropion, phentermine and Qsymia as examples ^[1]. Documentation of participation in a comprehensive weight-management program, such as Teladoc or another weight-loss program, is also required ^[1].

Two combinations are excluded: Zepbound will not be approved alongside another GLP-1 receptor agonist, and it will not be approved alongside another prior-authorization weight-loss medication ^[1]. Patients must also have tried the plan's preferred product unless a valid medical exception applies, such as inadequate response, intolerance or contraindication ^[1]. The policy does not list the preferred products in its text; it points to a separate formulary document ^[1].

Quantity limits and renewals

Approved requests are limited to 12 single-dose pens per 84 days. Initial approvals last six months, and renewals last 12 months ^[1]. For a renewal, the patient must have lost at least 5 percent of baseline body weight, or have maintained that initial 5 percent loss, and must still be participating in a weight-management program ^[1]. The dual-therapy exclusions and the preferred-product requirement also apply at renewal ^[1]. The policy states that current use of the drug, including samples, does not guarantee approval of coverage ^[1].

The prior-approval criteria are written for chronic weight management. The same document notes that Zepbound is FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity, and it does not describe separate criteria for that use ^[1].

Why it matters for patients

These requirements apply to the Federal Employee Program, which covers federal workers and annuitants, not to every commercial insurance plan ^[1]. Members already taking Zepbound under this program could see continued coverage depend on documented weight loss of at least 5 percent and on participation in a weight-management program ^[1].

For someone seeking coverage for the first time, the policy means producing records showing two oral medications were tried and failed, were not tolerated, or were contraindicated, along with proof of a weight-management program, before a prior authorization is reviewed ^[1]. All approved requests are subject to review by a clinical specialist for final validation and coverage determination once the required documentation is received ^[1].

Copay amounts are not addressed in this policy; it covers medical-necessity criteria and quantity limits only ^[1]. Zepbound carries a boxed warning about thyroid C-cell tumors, including medullary thyroid carcinoma, seen in rats, and the policy says the relevance to humans is unknown. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[1].

What happens next

The new criteria take effect July 1, 2026, for prior-approval and related claim reviews ^[1]. The policy's most recent review was dated June 11, 2026, and its history shows annual reviews, with the June 2026 entry described as an annual review and reference update ^[1]. Zepbound was first added to the FEP policy in January 2024 as a non-preferred option on the MedEx formulary ^[1]. It has not been disclosed how many FEP members currently take Zepbound or how many requests the new criteria would affect.